Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
JCR Pharmaceuticals Co., Ltd. (4552.T)
JPY524.00
+35.00 (+7.16%)
JP JPX Healthcare Drug Manufacturers - General
Address
3-19 Kasuga-cho 659-0021
Ashiya, JP
Ashiya, JP
CEO
Toru Ashida
Website
jcrpharm.co.jp
IPO
2005-11-17
ISIN JP3701000006
Also trades on
Other OTC · JCRRF (USD)
Tokyo Stock Exchange · 4552.T (JPY)
Description
JCR Pharmaceuticals Co., Ltd. is a specialized pharmaceutical firm primarily engaged in the creation, development, manufacturing, international trade, and distribution of medicinal products, regenerative therapies, and active pharmaceutical ingredients within Japan. The company offers a range of therapeutic solutions, including GROWJECT, which addresses growth hormone deficiency and short stature; IZCARGO, prescribed for Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion, utilized in the management of Fabry disease; and TEMCELL HS Inj, employed to treat acute graft-versus-host disease. Beyond its current offerings, JCR Pharmaceuticals is also developing Epoetin Alfa BS and Darbepoetin Alfa BS Injections, both intended for the treatment of renal anemia. Furthermore, the company markets various medical devices and laboratory instruments. Founded in 1975, its headquarters are situated in Ashiya, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY524.00
+35.00 (+7.16%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
666.3K
Beta
0.13
Float Shares
71.44M
Free Float %
58.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.60% | -8.46% | -19.16% | -24.89% | -21.33% | -27.93% | +8.97% | -55.77% | -85.00% | -25.73% | +191.65% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
524.00
Ratings Trend (MoM)
17% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 5 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.49
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - General: +6.6%+21.9% ★ Q1'26: +38.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+146.5% ★ Q1'26: +110.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%-17.9% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+1.1% Q1'26: +1.2% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+0.3% Q1'26: +0.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-1.5% ★ Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×18.04× Q1'26: 20.57× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 6 Rev. Ana. 5 EPS Ana. |
Mar 2027 6 Rev. Ana. 2 EPS Ana. |
Mar 2028 6 Rev. Ana. 6 EPS Ana. |
Mar 2029 4 Rev. Ana. 4 EPS Ana. |
Mar 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
16.86B
est: 16.80B (+0.3%)
|
17.44B
est: 17.87B (-2.4%)
|
18.09B
est: 18.48B (-2.2%)
|
20.59B
est: 20.80B (-1.0%)
|
23.16B
est: 22.50B (+3.0%)
|
24.78B
est: 25.54B (-3.0%)
|
30.09B
est: 28.42B (+5.9%)
|
51.08B
est: 49.48B (+3.2%)
|
34.34B
est: 38.99B (-11.9%)
|
42.87B
est: 40.21B (+6.6%)
|
33.07B
est: 37.65B (-12.2%)
|
38.90B
36.71B – 40.12B
+3.3% YoY
|
40.70B
37.49B – 42.14B
+4.6% YoY
|
38.37B
34.10B – 43.60B
-5.7% YoY
|
39.44B
38.33B – 40.54B
+2.8% YoY
|
43.68B
39.51B – 47.47B
+10.8% YoY
|
| EBITDA |
3.42B
est: 3.85B (-11.2%)
|
3.56B
est: 4.10B (-13.1%)
|
3.81B
est: 4.24B (-10.1%)
|
5.17B
est: 4.77B (+8.4%)
|
6.31B
est: 5.16B (+22.4%)
|
4.68B
est: 5.85B (-20.1%)
|
10.16B
est: 6.51B (+56.0%)
|
21.88B
est: 11.34B (+92.9%)
|
6.97B
est: 8.94B (-22.0%)
|
10.73B
est: 6.84B (+56.8%)
|
-3.47B
est: 6.41B (-154.1%)
|
6.62B
6.25B – 6.83B
+3.3% YoY
|
6.93B
6.38B – 7.17B
+4.6% YoY
|
6.53B
5.80B – 7.42B
-5.7% YoY
|
6.71B
6.52B – 6.90B
+2.8% YoY
|
7.43B
6.72B – 8.08B
+10.8% YoY
|
| EBIT |
2.07B
est: 2.72B (-24.1%)
|
2.15B
est: 2.90B (-25.7%)
|
2.36B
est: 3.00B (-21.2%)
|
3.79B
est: 3.37B (+12.3%)
|
4.97B
est: 3.65B (+36.3%)
|
3.25B
est: 4.14B (-21.6%)
|
8.27B
est: 4.61B (+79.6%)
|
19.94B
est: 8.02B (+148.6%)
|
4.98B
est: 6.32B (-21.2%)
|
7.53B
est: 4.14B (+82.0%)
|
-6.84B
est: 3.88B (-276.5%)
|
4.00B
3.78B – 4.13B
+3.3% YoY
|
4.19B
3.86B – 4.34B
+4.6% YoY
|
3.95B
3.51B – 4.49B
-5.7% YoY
|
4.06B
3.95B – 4.17B
+2.8% YoY
|
4.50B
4.07B – 4.89B
+10.8% YoY
|
| Net Income |
1.68B
est: 1.58B (+6.7%)
|
1.79B
est: 1.86B (-3.9%)
|
1.86B
est: 1.86B (+0.1%)
|
3.07B
est: 3.08B (-0.4%)
|
3.71B
est: 3.49B (+6.4%)
|
2.68B
est: 3.36B (-20.4%)
|
6.89B
est: 5.47B (+26.0%)
|
14.51B
est: 15.06B (-3.7%)
|
3.77B
est: 7.56B (-50.1%)
|
5.51B
est: 4.10B (+34.4%)
|
-4.76B
est: 409.48M (-1,262.0%)
|
2.18B
766.51M – 2.43B
+431.9% YoY
|
318.45M
232.98M – 403.92M
-85.4% YoY
|
2.56B
501.39M – 2.72B
+704.3% YoY
|
299.70M
45.64M – 553.77M
-88.3% YoY
|
2.20B
1.92B – 2.44B
+632.8% YoY
|
| SGA |
5.71B
est: 5.29B (+8.0%)
|
5.48B
est: 5.63B (-2.6%)
|
5.92B
est: 5.82B (+1.7%)
|
6.47B
est: 6.55B (-1.2%)
|
7.27B
est: 7.08B (+2.7%)
|
7.64B
est: 8.04B (-5.0%)
|
8.64B
est: 8.95B (-3.4%)
|
13.51B
est: 15.58B (-13.3%)
|
11.68B
est: 12.28B (-4.9%)
|
12.49B
est: 12.92B (-3.4%)
|
12.96B
est: 12.10B (+7.1%)
|
12.50B
11.80B – 12.89B
+3.3% YoY
|
13.08B
12.05B – 13.54B
+4.6% YoY
|
12.33B
10.96B – 14.01B
-5.7% YoY
|
12.67B
12.32B – 13.03B
+2.8% YoY
|
14.04B
12.70B – 15.26B
+10.8% YoY
|
| EPS |
13.21
est: 12.74 (+3.7%)
|
14.03
est: 15.04 (-6.7%)
|
14.74
est: 15.03 (-2.0%)
|
24.68
est: 24.89 (-0.8%)
|
30.17
est: 28.20 (+7.0%)
|
21.72
est: 27.16 (-20.0%)
|
55.80
est: 44.16 (+26.3%)
|
117.26
est: 121.63 (-3.6%)
|
30.34
est: 61.06 (-50.3%)
|
44.13
est: 32.84 (+34.4%)
|
-38.43
est: 3.37 (-1,238.8%)
|
10.87
6.28 – 19.95
+222.1% YoY
|
2.61
1.91 – 3.31
-76.0% YoY
|
16.09
4.11 – 22.25
+516.5% YoY
|
2.53
0.37 – 4.54
-84.3% YoY
|
18.00
15.77 – 20.03
+610.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
6.29B
OE per share TTM
50.11
Owner's Yield
8.93%
Maintenance CapEx ratio
137.72%
Maint CapEx / Avg PPE
71.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 29 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.06% | 219.2K | 0.58% |
| 2 | State Street SPDR S&P International Small Cap ETF GWX | 0.01% | 115.3K | 0.40% |
| 3 | Schwab International Small-Cap Equity ETF SCHC | 0.01% | 488.7K | 0.06% |
| 4 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 897.3K | 0.06% |
| 5 | iShares Core TOPIX ETF 1475.T | 0.00% | 691.9K | 0.05% |
| 6 | Amundi Japan TOPIX II UCITS ETF EUR Dist JPNU.L | 0.00% | 24.7K | 0.45% |
| 7 | Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO | 0.00% | 5.0K | 0.22% |
| 8 | Vanguard FTSE Pacific ETF VPL | 0.00% | 275.7K | 0.07% |
| 9 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 179.3K | 0.22% |
| 10 | Dimensional - International Small Cap ETF DFIS | 0.00% | 61.0K | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
461.5K
Shares Outstanding
121.98M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hiroshi Yoshimoto | Senior Advisor | — | — |
| Hiroyuki Fukuya | Exec Off, Dir of Legal & Compliance, Internal Control Dept and Chief Legal & Compliance Off | — | male |
| Hiroyuki Sonoda | President, Chief Scientific Officer & Representative Director | — | male |
| Katsuya Nishino | Executive Vice President | — | — |
| Shin Ashida | Founder & Director | — | male |
| Shinji Okamoto | Director of Human Resources Department & Administration Division | — | — |
| Takafumi Shimizu | Director of Marketing Dept. & Sales Division | — | — |
| Takayo Egawa | Senior Executive Officer & Director of International Affairs | — | — |
| Toru Ashida | Chairman of the Board | — | — |
| Tsuyoshi Tajir | Director of Marketing Dept. & Sales Division | — | — |
| Yoshihiro Ota | Director of Accounting Department & Corporate Strategy Department (Finance) | — | — |
| Yutaka Honda | Senior Managing Executive Officer, Exec Director of Administration Div. & Head of Exec Office | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4552.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
